Cargando…

Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis

AIM: To perform a systematic review and meta-analysis of Phase III randomized controlled trials (RCTs) to determine the incidence and risk of severe adverse events (AEs) with molecular targeted agents (MTAs) in advanced/metastatic gastric cancer (GC) patients. METHODS: A comprehensive literature sea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Liang, Liu, Yagang, Zhou, Wenyong, Li, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414625/ https://www.ncbi.nlm.nih.gov/pubmed/28490885 http://dx.doi.org/10.2147/OTT.S110431

Ejemplares similares

Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials
por: Li, Xiaofei, et al.
Publicado: (2018)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
por: Holmøy, Trygve, et al.
Publicado: (2019)

Current Molecular Targeted Agents for Advanced Gastric Cancer
por: Nie, Shanshan, et al.
Publicado: (2020)

Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents
por: Jordan, Emma J., et al.
Publicado: (2018)

Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis
por: Gu, Biao, et al.
Publicado: (2016)

An Updated Meta-Analysis of Fatal Adverse Events Caused by Bevacizumab Therapy in Cancer Patients
por: Huang, Hongxin, et al.
Publicado: (2014)

Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis
por: Liu, Tingting, et al.
Publicado: (2020)

S-1 and 5-Fluorouracil-related adverse events in patients with advanced gastric cancer: A meta-analysis
por: Hu, Qingqing, et al.
Publicado: (2023)

Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis
por: Feng, Yao-Ning, et al.
Publicado: (2023)

The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy
por: Buckley, S A, et al.
Publicado: (2015)

Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer
por: Higashi, Tetsuo, et al.
Publicado: (2020)

Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysis
por: Ren, Zheng, et al.
Publicado: (2017)

Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer
por: Wu, Jing, et al.
Publicado: (2017)

Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials
por: Yin, Xiaonan, et al.
Publicado: (2018)

Incidence and Risk of Fatal Adverse Events in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor 2-Targeted Agents: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials
por: Zhao, Bin, et al.
Publicado: (2019)

Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis
por: Jiang, Yi, et al.
Publicado: (2019)

Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma
por: Schwartz, Gabriel, et al.
Publicado: (2020)

Association between antenatal corticosteroid treatment and severe adverse events in pregnant women
por: Tsai, Hui-Ju, et al.
Publicado: (2023)

A pooled analysis of molecularly targeted agents for treatment of metastatic oesophago-gastric cancer in elderly patients
por: Lv, Hui, et al.
Publicado: (2020)

The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis
por: Kim, Bum Jun, et al.
Publicado: (2017)

Adverse events of methotrexate treatment in JIA
por: in ‘t Veld, J, et al.
Publicado: (2011)

Fatal Events Associated with Adverse Drug Reactions in the Korean National Pharmacovigilance Database
por: Jo, Hyeong-Geun, et al.
Publicado: (2021)

Molecular targeted therapy for the treatment of gastric cancer
por: Xu, Wenting, et al.
Publicado: (2016)

Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis
por: Wang, Xuewen, et al.
Publicado: (2020)

Association between antihypertensive treatment and adverse events: systematic review and meta-analysis
por: Albasri, Ali, et al.
Publicado: (2021)

Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis
por: Pei, Wen-Guang, et al.
Publicado: (2023)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020)

A simple endoscopic treatment for large gastric bezoars: the guidewire and snare method
por: Li, Yagang, et al.
Publicado: (2022)

Clinical Efficacy and Adverse Reactions of Bevacizumab plus Radiochemotherapy in the Treatment of Advanced Gastric Cancer
por: Wei, Fang
Publicado: (2022)

Prediction of severe adverse events, modes of action and drug treatments for COVID-19’s complications
por: Astore, Courtney, et al.
Publicado: (2021)

Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis
por: Xia, Ning, et al.
Publicado: (2015)

The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse events
por: Hehir, Michael K., et al.
Publicado: (2022)

Molecular targeted therapy for advanced gastric cancer
por: Kim, Jong Gwang
Publicado: (2013)

Adverse event profiles of adjuvant treatment with opicapone in Parkinson’s disease: A systematic review and meta-analysis
por: Xie, Luwen, et al.
Publicado: (2022)

Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis
por: Liu, Wanshu, et al.
Publicado: (2019)

Targeted agents for second-line treatment of advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rrpe9nirnon4b1jmq1i3npnsbs